4
Impact 6/10
Insider Transaction
$NONE · Tananbaum Steven A.
Summary
GoldenTree Asset Management LP, a 10% owner of Keenova Therapeutics plc, reported a purchase of 463,000 shares at $91.00 per share, totaling $42,133,000. The transaction was not made under a 10b5-1 trading plan. Following the purchase, GoldenTree holds 8,442,827 shares.
Key points
- GoldenTree purchased 463,000 shares at $91.00 each, totaling $42,133,000.
- Post-transaction, GoldenTree holds 8,442,827 shares as a 10% owner.
- The purchase was not executed under a 10b5-1 trading plan.
- GoldenTree is a 10% owner, not an officer or director of Keenova Therapeutics.
Insider transaction
InsiderGOLDENTREE ASSET MANAGEMENT LP (10% Owner)
Actionpurchase
Shares463,000
Price$91.00
Total value$42,133,000.00
Owned after8,442,827
Market impact
Price data unavailable.
Why this matters
A $42.1M discretionary buy by a 10% owner is a high-conviction signal, especially without a 10b5-1 plan.
Sector context
_Not applicable._
Risk factors
_Not applicable._
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.